Full-Time
Senior Financial Analyst
ENOVIS
1,001-5,000 employees
Global medical technology company; orthopedic solutions
No salary listed
Lewisville, TX, USA
In Person
On-site in Lewisville, Texas; occasional travel up to 10%.
Bachelor's
 Finance & Banking (1) |
|---|
Get referred to ENOVIS
See people who can refer or advise you
- Bachelor's degree in Finance, Accounting, or related discipline
- 5+ years in a financial planning & analysis environment
- Strong organizational skills to manage multiple workstreams, while prioritizing critical needs across multiple businesses to achieve results
- Excellent interpersonal, written and verbal communication skills; Ability to effectively communicate with individuals across functions and at all organizational levels, including executive management and global personnel
- Advanced proficiency in Microsoft Excel, Word, PowerPoint
- Experience in Oracle, Power BI, and HFM
- Occasional travel, 10% or less expected
- Working with leadership on understanding the financial impacts of strategic initiatives and provides analytical insight
- Consolidated financial reporting and analysis; prepares, publishes, and presents critical financial reporting to all levels of business leadership
- Assist with budgeting and forecasting process and development
- Financial analysis and planning for functional leaders
- Review and update forecasts based on actual performance and changes in business conditions
- Analyze historical financial data and industry trends to create accurate projections
- Provide insightful commentary on financial results and variances against budgets/forecasts
- Assist in developing financial models to support decision-making processes
- Work with senior management to align financial strategies with overall business objectives
- Develop and maintain management dashboards to facilitate data-driven decision-making
- Ensure accuracy and completeness of financial information presented to management
- Develop and implement financial strategies to support project goals and objectives
- Support the development of financial models and other analytical tools to enhance the efficiency of business applications and processes
- Compile and analyze financial information to prepare journal entries for month/quarter end close processes; supports the financial period close process and cadence through reporting, accounting entries, and variance analysis
- Ad hoc analyses to support business needs
- Initiate process improvements and oversees the continued development of budgeting, financial forecasting, operational support, and complex modeling tools; Implement continuous improvement initiatives to improve forecast process including forward-looking trend analysis and establishing leading indicators
- On an as needed basis, may be asked to assist other members of the finance team in new system implementation efforts, research projects, and new transaction, merger, or acquisition evaluation, accounting and integration
Enovis develops medical devices and services to improve patient outcomes and restore mobility. It operates Prevention & Recovery with orthopedic braces, soft goods, vascular therapy, compression garments, and hot/cold therapy, and Reconstructive with joint implants and surgical tools such as Novastep. It differentiates itself through a broad clinically oriented portfolio, a global footprint, and the EGX continuous improvement program, plus the LimaCorporate acquisition expanding its transatlantic reach. Its goal is to provide better patient outcomes and mobility worldwide through sustained growth and operational excellence.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
2022
Get referred to ENOVIS
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 organic growth hit 5%, with hips and knees up 8%.
- Free cash flow turned positive in first half 2026, improving $27 million year over year.
- Medicare reversed bone-stimulator reimbursement cuts in July 2026, lifting Enovis shares 15%.
What critics are saying
- Encore Medical’s EMPOWR 3D KNEE recall stayed open on February 25, 2026.
- PNR grew only 3% organically in Q2 2026, with Middle East conflict cutting 100 basis points.
- If ARVIS adoption stalls, Enovis remains a midscale orthopedic consolidator against Zimmer Biomet and Stryker.
What makes ENOVIS unique
- Enovis pairs DonJoy, Aircast, and LimaCorporate implants across prevention and reconstruction.
- ARVIS reached full U.S. commercial launch on August 6, 2026, expanding robotic surgery credibility.
- Over 80% of new instrumentation sets now go to competitive users, proving switching power.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Legal Services
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 30%Enovis Corp reported 5% organic growth in Q2 2026, with US reconstruction growing 6% and hips/knees up 8%. The medical device company's innovation portfolio showed strong momentum, with its Avis robotic system now in full commercial launch and over 80% of new instrumentation sets going to competitive users. Adjusted gross margins improved by 120 basis points, driven by productivity and mix improvements despite tariff and inflationary pressures. Free cash flow turned positive in the first half, improving by $27 million year-over-year, whilst leverage decreased to 3.1x. However, the company's Prevention and Recovery (PNR) segment grew only 3% organically, with international markets affected by Middle East conflict creating a 100 basis point headwind. Enovis faces $10 million in full-year inflationary pressure from raw materials and freight. Management reaffirmed 2026 guidance and expressed confidence in accelerating Q4 growth, supported by new product launches.
Medical technology company Enovis met Wall Street's revenue expectations in Q2 2026, with sales rising 3.2% year on year to $582.8 million. The company's non-GAAP profit of $0.90 per share exceeded analysts' consensus estimates by 6.3%. Enovis reconfirmed its full-year revenue guidance of $2.34 billion at the midpoint, close to analysts' estimates. The company also maintained its full-year adjusted EPS guidance of $3.63 at the midpoint. Operating margin improved to 3%, up from -3% in the same quarter last year. Free cash flow margin reached 5.3%, compared to 0.6% year on year. Chief executive Damien McDonald said the results reflect "a more focused organisation and a portfolio that has been meaningfully reshaped over the past several years." Enovis develops medical devices for orthopaedic care, including injury prevention and joint replacement.
Enovis (NYSE:ENOV) raised to Hold at Zacks Research. July 31, 2026 Key points. * Zacks Research upgraded Enovis from "strong sell" to "hold," while the broader analyst consensus remains "Moderate Buy" with an average price target of $41.86. * Enovis reported quarterly EPS of $0.89, exceeding estimates of $0.82, while revenue rose 5.4% year over year to $589.15 million. Analysts expect full-year EPS of $3.12, compared with the company's 2026 guidance range of $3.52-$3.73. * Shares opened at $29.32 after recently trading down 3.1%; insiders purchased 4,200 shares worth about $92,000 during the last quarter, and institutional investors own 98.45% of the stock. * MarketBeat previews the top five stocks to own by August 1st. Enovis (NYSE:ENOV - Get Free Report) was upgraded by investment analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a research note issued on Wednesday,Zacks.com reports. A number of other brokerages also recently commented on ENOV. Wall Street Zen raised shares of Enovis from a "hold" rating to a "buy" rating in a report on Monday, July 6th. BTIG Research reissued a "buy" rating and set a $39.00 price objective on shares of Enovis in a research note on Friday, May 22nd. Evercore set a $32.00 price objective on Enovis in a research report on Monday, July 6th. Wells Fargo & Company decreased their price objective on Enovis from $42.00 to $40.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Finally, BMO Capital Markets began coverage on Enovis in a research note on Wednesday, July 8th. They issued an "outperform" rating and a $29.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $41.86. Enovis trading down 3.1%. Shares of ENOV opened at $29.32 on Wednesday. The stock has a market capitalization of $1.69 billion, a PE ratio of -1.47 and a beta of 1.39. The company's fifty day moving average is $23.96 and its 200 day moving average is $23.78. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. Enovis has a fifty-two week low of $19.14 and a fifty-two week high of $34.28. Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million during the quarter, compared to analyst estimates of $572.02 million. During the same quarter last year, the business earned $0.81 earnings per share. Enovis's quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts expect that Enovis will post 3.12 earnings per share for the current fiscal year. Insider activity at Enovis. In related news, insider Oliver Engert purchased 1,200 shares of the business's stock in a transaction dated Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have bought 4,200 shares of company stock valued at $92,084 in the last quarter. Corporate insiders own 2.90% of the company's stock. Institutional investors weigh in on Enovis. Large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in shares of Enovis by 1.2% in the 2nd quarter. California State Teachers Retirement System now owns 51,713 shares of the company's stock worth $1,622,000 after acquiring an additional 621 shares in the last quarter. MGO One Seven LLC lifted its stake in shares of Enovis by 9.4% during the 4th quarter. MGO One Seven LLC now owns 7,581 shares of the company's stock worth $202,000 after purchasing an additional 650 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company's stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Empowered Funds LLC grew its stake in Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company's stock valued at $249,000 after purchasing an additional 749 shares during the last quarter. Finally, Inscription Capital LLC grew its stake in Enovis by 9.4% in the fourth quarter. Inscription Capital LLC now owns 11,869 shares of the company's stock valued at $316,000 after purchasing an additional 1,016 shares during the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors. About Enovis. Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation. The company's flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Enovis, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list. While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Enovis Corporation's shares rose 2.8% after announcing the US launch of CT-RevitL, a veterinary laser therapy system from its Companion Animal Health business. The system uses photobiomodulation therapy to manage pain, accelerate tissue healing, reduce inflammation, and support post-operative recovery in animals. The product is immediately available to veterinary practices across the United States, with international distribution planned for the future. According to the company, laser therapy is amongst the fastest-growing treatment methods in veterinary medicine. The stock remains 20.5% below its 52-week high of $33.32 from September 2025. Last week, Enovis shares jumped 15% after Medicare reversed previously announced reimbursement cuts for the company's non-invasive bone growth stimulators.
Enovis Corporation has launched CT-RevitL, a new laser therapy system for veterinary care in the United States. The device is part of the company's Companion Animal Health division, which Enovis describes as the US market leader in veterinary therapeutic laser technology. CT-RevitL uses COMPASS technology, an intelligent treatment guidance system designed to deliver precise dosing and reduce treatment variability. The system is intended to help manage pain, accelerate tissue healing, and support post-operative recovery in animals. The launch is backed by over 150 published studies on photobiomodulation therapy. Companion Animal Health has been developing laser therapy applications for more than 15 years. The system became available to US veterinary practices on 13 July 2026, with international availability planned for later phases.